Zevra Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent
Zevra Therapeutics, Inc. (ZVRA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent of -0.29% for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-28.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization · last filed 2020-02-28
- Zevra Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, amortization, percent for fiscal 2019 was -0.29%.
- Zevra Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, amortization, percent for fiscal 2017 was -1.22%.
- Zevra Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, amortization, percent for fiscal 2016 was -3.15%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent 12 month |
|---|---|
| 2019-12-31 | -0.29% 10-K · filed 2020-02-28 |
| 2017-12-31 | -1.22% 10-K · filed 2019-03-01 |
| 2016-12-31 | -3.15% 10-K · filed 2018-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |